A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months, compared with 12.7 months for Imfinzi alone, in patients whose cancer had not progressed after initial Imfinzi and chemotherapy. Nearly 80% of patients on the combination were alive at one year, versus 53% on Imfinzi alone. Imdelltra posted $288 million in second-quarter sales, up 115% year over year, after $627 million in global sales in 2025. Amgen said the results suggest earlier use of the drug could meaningfully alter the course of the disease, though the trial did not compare the combination with other first-line treatments.
Summary written by Upside AI from the original article. Read the source for full details.
Keywords
pharmaceuticalshealthcareAmgen
Open a keyword to see other news on the same topic.
Related news
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Amgen vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ?
This comparison pits Amgen (AMGN) against Bristol Myers Squibb (BMY), with Amgen focused on biologics and BMY strong in oncology and hematology. In FY 2025, Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion, a net margin near 21%, and free cash flow of nearly $8.1 billion. BMY generated revenue of about $48.2 billion, nearly flat, with net income of about $7.1 billion, a net margin near 14.6%, and free cash flow of about $12.8 billion. Amgen faces drug pricing pressure, an IRS tax dispute and biosimilar competition, while BMY relies heavily on Eliquis, which faces generic competition. The article describes BMY as cheaper, but says much of the difficulty appears priced in, so it is not an obvious buy right now.
- 2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
The article examines Johnson & Johnson (JNJ) and Amgen (AMGN), two dividend stocks that have outperformed the market in 2026. For J&J, revenue and earnings beat expectations and guidance was slightly raised, but its medtech unit faces weaker Impella demand and a Class 1 recall in the U.S.; the article still sees long-term prospects intact, citing new drug launches, the OTTAVA surgical system, a proposed $5.5 billion talc settlement and a 64-year dividend increase streak. Amgen's second-quarter revenue rose 10% to $10.1 billion despite FDA moves to remove Tavneos and falling denosumab sales after losing exclusivity. The article says growth drivers such as Tezspire, Tepezza and the MariTide obesity candidate could offset these headwinds.
- Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
The article compares three drugmakers: Biogen (BIIB), Amgen (AMGN) and Gilead (GILD). Biogen closed at $225.71 on October 9 after returning 30.5% over six months, Amgen closed at $414.87 (up 18.6%), and Gilead closed at $151.17 (up 8.8%). Gilead posted a net loss of more than $3 billion over the past year yet generated the most cash in the group and the highest return on assets at 14.09%, which the author attributes to accounting charges. Revenue grew roughly 10% at Gilead and Amgen versus 3.40% at Biogen, whose earnings fell 84.60% in the latest quarter. Biogen has the lowest forward P/E at 13.65 times, versus 15.29 for Gilead and 16.94 for Amgen, and the author sees Gilead as worth its small premium.
- Moderna's Stock Just Stumbled. Is It a Buy on the Dip?
Moderna shares fell 17% in one session after leaked data from a phase 3 trial of intismeran autogene combined with Merck's Keytruda, though the leaked results showed the drug combo cut the risk of recurrence or death by 42% in certain melanoma patients versus Keytruda alone, and by 58% after six months. The stock has still climbed more than 500% this year, trading near $200 versus an average Wall Street 12-month price estimate of $135. The author sees the dip as possibly a buying opportunity for long-term investors who want to open or add to a position, while cautioning that the stock remains sensitive to trial data and may see further pullbacks. Moderna currently has four commercialized products in the U.S., all respiratory vaccines.
- Why Healthcare ETFs Are Hovering Around One-Year Highs
Healthcare ETFs are near one-year highs, supported by an improving earnings outlook, positive trial data, relatively attractive valuations, and a shift out of crowded AI/tech trades. The State Street Health Care Select Sector SPDR ETF (XLV) rose 23.2% over six months (as of Oct. 20, 2026), versus about 9.2% for the State Street SPDR S&P 500 ETF Trust (SPY). S&P 500 healthcare companies are expected to post double-digit earnings growth from Q4 2026 through 2027, and sector M&A value has reached nearly $284 billion this year, approaching 2025's $306 billion. Notable 2026 readouts include Eli Lilly's retatrutide (28.3% average weight loss over 80 weeks at the 12-mg dose) and Vertex's povetacicept (49.8% proteinuria reduction vs. placebo at Week 36). The article also profiles the VanEck Biotech ETF (BBH, up 30.8% YTD) and Invesco Biotechnology & Genome ETF (PBE, up 20.5% YTD).
Related markets
Latest news
- Crypto under weekend pressure, bitcoin slides below $80,000 on U.S. Middle East evacuations
Bitcoin fell below $80,000 on Saturday, hitting its weakest level in more than a month after dropping 2.2% over 24 hours to $79,700. Ether, XRP and Solana declined 3%–4% as crypto prices fell broadly. The WSJ reported that the U.S. is rapidly evacuating personnel from embassies and military bases across the Middle East, citing intelligence that Iran is preparing attacks against Americans. In a memo to Secretary of State Marco Rubio, Director of National Intelligence Jay Clayton said Iran has substantially increased efforts to target U.S. personnel, and the evacuations go well beyond earlier orders for some diplomatic staff in Saudi Arabia to leave. President Trump has threatened a re-escalation of the war against Iran after the midterms in early November.
- US objective is no more oil, nuclear issues, its total destruction of Iran: Foreign Affairs Expert Waiel Awwad
Foreign affairs expert Waiel Awwad told ANI that Washington's goal regarding Iran goes beyond nuclear issues and oil, aiming at regime change and the destruction of Iran, which would make Israel a dominant force in the region. He said the posture is also shaped by domestic political pressure ahead of the midterm elections, and that Iran views the conflict as an 'existential war'. With crude oil at USD 117 per barrel, the highest since April, Awwad highlighted economic pressures on India's energy security and inflation. The IRGC claimed Iran controls the Strait of Hormuz, and said two supertankers carrying more than 4.5 million barrels of crude struck naval mines while using what Tehran called an unauthorised southern route. Iran's Chief of General Staff Ali Abdollahi said Iran would not allow US military vessels into the Persian Gulf, while US Ambassador Sergio Gor said American LPG rose to 67% of India's imports from below 10%.
- TSA Wealth Managment LLC Sells 30 , 417 Shares of Invesco S & P 500 Momentum ETF $SPMO
TSA Wealth Managment LLC cut its stake in the Invesco S&P 500 Momentum ETF (SPMO) by 76.1% in the third quarter, selling 30,417 shares and leaving it with 9,547 shares, according to an SEC filing. The holding was worth $1,447,000 at the end of the most recent quarter. Other institutional investors also changed their positions, including Blue Trust Inc., which raised its stake by 35.8% in the first quarter to 353 shares. SPMO fell $0.16 to $138.66 in midday trading on Friday, with volume of 2,009,242 shares versus an average of 1,947,640. The fund has a market capitalization of $21.46 billion, a P/E ratio of 29.51, a beta of 1.10, and a 12-month range of $107.24 to $162.30. The ETF tracks 100 S&P 500 components with the strongest volatility-adjusted momentum and was launched on Oct 9, 2015, and is managed by Invesco.
- WASHINGTON TRUST Co Acquires New Holdings in iShares TIPS Bond ETF $TIP
Washington Trust Co took a new position in the iShares TIPS Bond ETF (TIP) in the third quarter, according to Holdings Channel. The firm bought 10,804 shares worth about $1,124,000. Several other institutional investors and hedge funds also changed their holdings, with Realta Investment Advisors raising its stake by 159.2% in the first quarter to 521 shares, and NBT Bank N A NY raising its stake by 374.5% to 522 shares. Hedge funds and institutional investors own 63.62% of the stock. TIP fell $0.09 to $106.24 on Friday, with a market capitalization of $14.55 billion. The fund tracks the Barclays U.S. Treasury Inflation Protected Securities (TIPS) Index (Series-L), which includes investment-grade inflation-protected Treasury securities with at least one year to maturity and face value of $250 million or more.
- Halloween candy sales are off to a slow start amid high chocolate prices and affordability concerns
Halloween candy sales have started slowly this year as U.S. consumers grapple with high living costs and expensive chocolate. NielsenIQ data shows sales fell 6.7% in the month ending Oct. 17 from a year earlier, after an 11.7% drop in mid-September erased the preseason gains seen in the previous two years. NielsenIQ's Chris Costagli said high gas prices, now averaging $4.29 per gallon, have worsened affordability concerns and dampened demand. Candy and gum prices rose 44% over five years versus 22.5% for all food eaten at home, largely due to cocoa prices that hit a record in January 2025 amid poor West African weather and speculative trading. Non-chocolate candy, about 3% cheaper than last year, has not seen a sales lift, and Circana's Sally Lyons Wyatt wonders whether shoppers are waiting until closer to Halloween to buy.
- US objective is no more oil, nuclear issues, its total destruction of Iran: Foreign Affairs Expert Waiel Awwad
Foreign affairs expert Waiel Awwad told ANI that Washington's goal regarding Iran goes beyond nuclear issues and oil, aiming at regime change and the destruction of Iran, which would make Israel a dominant force in the region. He said the posture is also shaped by domestic political pressure ahead of the midterm elections, and that Iran views the conflict as an 'existential war'. With crude oil at USD 117 per barrel, the highest since April, Awwad highlighted economic pressures on India's energy security and inflation. The IRGC claimed Iran controls the Strait of Hormuz, and said two supertankers carrying more than 4.5 million barrels of crude struck naval mines while using what Tehran called an unauthorised southern route. Iran's Chief of General Staff Ali Abdollahi said Iran would not allow US military vessels into the Persian Gulf, while US Ambassador Sergio Gor said American LPG rose to 67% of India's imports from below 10%.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.